Court Deals Blow To Mylan In Norvasc Dispute
A district court has shot down Mylan Laboratories Inc.'s bid to require the U.S. Food and Drug Administration to relist Pfizer's patent for Norvasc on its patent register in order for...To view the full article, register now.
Already a subscriber? Click here to view full article